A Survey of Midazolam in People With Status Epilepticus
Sponsored by Takeda
About this trial
Last updated 2 years ago
Study ID
TAK-815-5001
Status
Recruiting
Type
Observational
Placebo
No
Accepting
All Ages
All Sexes
Not accepting
Healthy Volunteers
Trial Timing
Started 5 years ago
What is this trial about?
This study is a survey in Japan of midazolam oromucosal solution used to treat people
with status epilepticus. The study sponsor will not be involved in how the participants
are treated but will provide instructions on how the clinics will record what happens
during the study.
The main aim of the study is to check for side effects related from midazolam oromucosal
solution and to check if midazolam oromucosal solution improves symptoms of status
epilepticus. During the study, participants with status epilepticus will take midazolam
oromucosal solution according to their clinic's standard practice. The study doctors will
check for side effects from midazolam for 6 months.
What are the participation requirements?
Inclusion Criteria
Must be with nonconvulsive status epilepticus.
Exclusion Criteria
Cannot have a history of hypersensitivity to any component of midazolam.
Study Document Downloads
Subscribe and get notified when study documents are available.
For more information, view the full study details:
